Our Company

Board of Directors

Robert S. Radie

Chairman

Robert Radie has served as a Director on our Board since March 2020.

Mr. Radie has more than three decades of industry experience, working in both public and private pharmaceutical and biotech companies across a range of therapeutic areas. He has held senior executive positions in several companies, including serving as Chief Executive Officer of Zyla Life Sciences, Topaz Pharmaceuticals, Inc., and Transmolecular, Inc. Mr. Radie also served as Chief Business Officer at Prestwick Pharmaceuticals, Inc., Morphotek, Inc., and Senior Vice President of Strategy and Planning at Vicuron Pharmaceuticals, Inc. Mr. Radie began his career at Eli Lilly and Company, where he worked for 18 years in sales and marketing positions with increasing levels of responsibility.

Mr. Radie holds several Board positions, including Paratek Pharmaceuticals, a public biopharmaceutical company; LPSA, the Pennsylvania industry advocacy group; and Horse Power for Life, a non-profit organization dedicated to improving the quality of life for individuals diagnosed with cancer. He previously served on the Boards of Veloxis Pharmaceuticals and Affinium Pharmaceuticals, a private specialty pharmaceutical company.

Mr. Radie received his B.S. in Chemistry from Boston College.


John Cooper

Director

John Cooper has served as a Director on our Board and Chair of the Audit Committee since September 2017.

Mr. Cooper’s career spans over 30 years of senior executive experience managing publicly-traded companies in the life sciences industry. He has played key leadership roles building companies with transformational medical technologies, including the first FDA approved synthetic peptide-containing pulmonary surfactant for premature infants with severe respiratory disease and the second FDA approved blood diagnostic test for HIV. Mr. Cooper has significant experience in corporate and organization development, raising capital, mergers and acquisitions, strategic alliances, investor relations, and corporate governance. Over his career, Mr. Cooper has raised approximately $1 billion in capital through various financing and strategic transactions. Currently, Mr. Cooper provides corporate development and financial advisory services to emerging public and private companies in the life sciences industry.

Mr. Cooper held executive leadership positions for Windtree Therapeutics (formerly Discovery Laboratories), a specialty biopharmaceutical company focused on respiratory therapeutics, from 2001 to 2016. His roles included President, Chief Executive Officer and Member of the Board of Directors, President and Chief Financial Officer, Executive Vice President and Chief Financial Officer. Prior to Discovery Labs, Mr. Cooper served as Senior Vice President and Chief Financial Officer at Chrysalis International Corporation (acquired by Phoenix Life Sciences) and its predecessor DNX Corporation, where he managed its initial public offering and negotiated and integrated several strategic acquisitions. Previously, Mr. Cooper served in senior financial management and executive committee roles at ENI Diagnostics (acquired by Pharmacia AB).

Mr. Cooper received his B.S. in Commerce from Rider University and holds a CPA designation.


Allen R. Nissenson, M.D.

Director

Dr. Nissenson has served as a Director on our Board since June 2020.

Dr. Nissenson has served as Emeritus Chief Medical Officer of DaVita Kidney Care, a division of DaVita HealthCare Partners, since January 2020. He previously served as Chief Medical Officer of DaVita Kidney Care from August 2008 to December 2019. Dr. Nissenson is also currently an Emeritus Professor of Medicine at the David Geffen School of Medicine at University California Los Angeles, where he previously served as Director of the Dialysis Program and Associate Dean. He has served on the board of Angion Biomedica Corp., a late-stage biopharmaceutical company, since January 2020. He is the immediate past Chair of Kidney Care Partners and immediate past Co-Chair of the Kidney Care Quality Alliance. He is a former president of the Renal Physicians Association and current member of the Government Affairs Committee. Dr. Nissenson also previously served as President of the Southern California End-Stage Renal Disease Network, as well as Chair of the Medical Review Board. Dr. Nissenson earned his B.S. from Northwestern University and his M.D. from Northwestern University Medical School.


Mark Ravich

Director

Mark Ravich has served as a Director on our Board since June 2017.

Mr. Ravich is the President of Tri-Star Management, which he co-founded in 1998. Additionally, he serves as the chief manager of various real estate entities. He is also a Director of Dilion Technologies and Orchids Paper Products Company, where he serves as Chairman of its Governance Committee and a Member of its Audit Committee. Previously, from 1990 until its sale in 1998, Mr. Ravich served as the Chief Executive Officer and a Director of Universal International.

Mr. Ravich received his BSE and MBA, Magna Cum Laude, from the Wharton School of the University of Pennsylvania.


Andrea H. Smiley

Director

Andrea Heslin Smiley joined the Rockwell Medical Board of Directors in December 2020. She currently serves as President and Chief Executive Officer of VMS BioMarketing. She joined VMS BioMarketing, a leading provider of patient and healthcare provider support, in 2008, and has served as its President and Chief Executive Officer since 2011. Within her first year as CEO, she spun-off commoditized business units and focused the company on impacting patient adherence and outcomes, all the while establishing VMS BioMarketing as the leading provider and growth leader of clinical nurse educator patient support solutions.

Prior to joining VMS BioMarketing, Ms. Smiley spent 18 years at Eli Lilly and Company in various positions of increasing responsibility in finance, business development, corporate affairs, brand management and business unit leadership roles. She was the marketing leader for the launch of Humalog® Mix75/25™, she led sales and marketing for Humatrope®, she was responsible for the development and launch of Forteo® and she was the business unit leader of Lilly’s women’s health business, among other programs. Earlier in her career, Ms. Smiley worked as a management consultant for Putnam Associates, where she led consulting teams and advised brands in the biotechnology, pharmaceutical and managed healthcare fields on product launches and access strategies. She is a regular speaker and panel member on patient adherence, patient services and women’s leadership topics at biopharmaceutical industry conferences.

Ms. Smiley serves on the board of numerous nonprofit organizations including the Indiana Alzheimer’s Association, Summer Stock, Indiana Salvation Army and the Lung Force Women’s Cabinet. She received a gubernatorial appointment to the Indiana Commission for Women. Ms. Smiley earned her Bachelor of Arts degree in economics from DePauw University, where she was an Honors Management Fellow.


Mark Strobeck, Ph.D.

Director

Dr. Strobeck has held leadership positions in both emerging biotechnology and pharmaceutical companies for more than twenty years. Most recently, he served as Managing Director of Aquilo Partners, LP, a life sciences investment bank. He previously served as Executive Vice President and Chief Operating Officer of Assertio Holdings, Inc., a pharmaceutical company. Prior to that, Dr. Strobeck was Executive Vice President and Chief Operating Officer of Zyla Life Sciences, a pharmaceutical company, from September 2015 through its merger with Assertio Holdings, Inc. in May 2020, and previously served as Zyla’s Chief Business Officer. He served as President and Chief Executive Officer and a director of Corridor Pharmaceuticals, Inc., a pharmaceuticals company, which was acquired by AstraZeneca plc in 2014. Dr. Strobeck served as Chief Business Officer of Topaz Pharmaceuticals Inc., a specialty pharmaceutical company acquired by Sanofi Pasteur in the fourth quarter of 2011. From January 2008 to May 2010, Dr. Strobeck served as Chief Business Officer of Trevena, Inc.. Prior to joining Trevena, Dr. Strobeck held management roles at GlaxoSmithKline plc, a pharmaceuticals company, and venture capital firms SR One Limited and EuclidSR Partners, L.P. Dr. Strobeck currently serves on the board of directors of Horse Power For Life, a nonprofit organization dedicated to improving the quality of life for individuals diagnosed with cancer, a position he has held since 2012. Dr. Strobeck received his B.S. in Biology from St. Lawrence University and his Ph.D. in Pharmacology and Biophysics from the University of Cincinnati and completed his post-doctoral fellowship at the University of Pennsylvania.